Abbott Reports Fourth-Quarter and Full-Year 2024 Results; Issues 2025 Financial Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Abbott Labs (ABT) PT Raised to $140 at BTIG
January 22, 2025 1:54 PM ESTBTIG analyst Marie Thibault raised the price target on Abbott Labs (NYSE: ABT) to $140.00 (from $139.00) while maintaining a Buy rating.
The analyst comments "Abbott reported a Q4 total revenue miss, much of which we attribute to greater Fx headwinds and lower-than-expected COVID testing revenue, and adj. EPS in line with expectations (see our flash note here). In our view, the main message on the call was the positive 2025 outlook, which called for above-consensus organic sales growth, a return to DD adj. EPS growth, and an impressive 150 bps of... More
